Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
8,165,808
-
Total 13F shares
-
83,252,102
-
Share change
-
+18,911,786
-
Total reported value
-
$57,777,566
-
Put/Call ratio
-
279%
-
Price per share
-
$0.69
-
Number of holders
-
80
-
Value change
-
+$13,851,989
-
Number of buys
-
39
-
Number of sells
-
51
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q1 2024
As of 31 Mar 2024,
Atara Biotherapeutics, Inc. - Common Stock (ATRA) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
83,252,102 shares.
The largest 10 holders included
EcoR1 Capital, LLC, Redmile Group, LLC, BlackRock Inc., BANK OF AMERICA CORP /DE/, CITADEL ADVISORS LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, Boxer Capital, LLC, Vestal Point Capital, LP, and ACADIAN ASSET MANAGEMENT LLC.
This page lists
80
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.